Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108771 · ClinicalTrials.gov registry record · Phase 2
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain
A Phase 2 study of Pain, sponsored by ZARS Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 202
- Enrollment target
- 13
- Study locations
NCT00108771: Completed Phase 2 study of Pain, sponsored by ZARS Pharma.
NCT00108771 is a Phase 2 study of Pain that has completed, run by ZARS Pharma. The registered enrollment target is 202 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (34% lower). The trial reports 13 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00108771, a Phase 2 study of Pain, has completed, sponsored by ZARS Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 202 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness of the Matrix Fentanyl Patch ZR-02-01 in providing pain relief.
Primary Outcome
The Pain,Stiffness and Physical Function subscales of the WOMAC Knee and Hip Osteoarthritis Index (5-point Likert scale: none through extreme) was employed. The subscales consist of 24 questions (5 pain, 2 stiffness and 17 physical function)
Conditions Studied
Interventions
- DRUG Placebo Patch
- DRUG ZR-02-01 Fentanyl Transdermal Matrix Patch
Study Locations (13)
California
- Sharp Rees-Stealy Medical Group - San Diego
- San Diego Arthritis Medical Clinic - San Diego
- Boling Clinical Trials - Upland
Florida
- Radiant Research - Daytona Beach
- Ocala Rheumatology - Ocala
- Tampa Medical Group - Tampa
Arizona
- Arizona Reserach Center - Phoenix
- Redpoint Research - Phoenix
Massachusetts
- Pain Trials Center - Brigham & Women's Hospital - Boston
- Phase III Clinical Trials - Fall River
New York
- Beth Israel Medical Center - New York
- Analgesic Development Ltd. - New York
Louisiana
- New Orleans Center for Clinical Research - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
What the finished NCT00108771 record still lists
NCT00108771 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo Patch is the first listed.
NCT00108771 lists 13 locations in 6 states (California, Florida, Arizona).
Frequently Asked Questions
What is clinical trial NCT00108771 about?
NCT00108771 is a clinical study titled "Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain". The purpose of this study is to evaluate the effectiveness of the Matrix Fentanyl Patch ZR-02-01 in providing pain relief.
What is the current status of trial NCT00108771?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2004-04. Estimated completion is 2006-09.
What conditions does trial NCT00108771 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT00108771?
The interventions under investigation include: Placebo Patch (DRUG), ZR-02-01 Fentanyl Transdermal Matrix Patch (DRUG).
Who is sponsoring clinical trial NCT00108771?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00108771 being conducted?
This trial has 13 study locations across Arizona, California, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00108771's enrollment target sits among peer trials
202 86th of 374 higher than 289 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Neural Correlates of Hypoalgesia Driven by Observation
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
-
Pain After Buffered Vs Non Buffered Articaine
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia